BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2025 6:25:21 AM | Browse: 78 | Download: 272
 |
Received |
|
2025-10-27 03:28 |
|
Peer-Review Started |
|
2025-10-27 03:28 |
|
First Decision by Editorial Office Director |
|
2025-10-30 08:52 |
|
Return for Revision |
|
2025-10-30 08:52 |
|
Revised |
|
2025-10-30 14:51 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-20 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-20 05:53 |
|
Articles in Press |
|
2025-11-20 05:53 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-09 11:04 |
|
Publish the Manuscript Online |
|
2025-12-23 06:25 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abdellatif Bouayad |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abdellatif Bouayad, Associate Professor, MD, Department of Immunology, Faculty of Medicine and Pharmacy Oujda, Mohammed First University, Mohammed V Avenue, Oujda-Angad 60049, Oriental, Morocco. abdellatifbouayad@hotmail.fr |
| Key Words |
Ectonucleoside triphosphate diphosphohydrolase 6; Cancer; Prognosis; Therapy; Antitumor immunity |
| Core Tip |
Ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6) has dual effects on cancer development and progression, influencing immune surveillance and immune evasion through tumor microenvironment modulation. It serves as a promising novel molecular biomarker for prognosis and for predicting cancer therapy responses. Furthermore, ENTPD6-derived neopeptide vaccines, as well as adoptive T-cell transfer using T cells engineered with T-cell receptors targeting ENTPD6, may constitute promising strategies in cancer immunotherapy. |
| Publish Date |
2025-12-23 06:25 |
| Citation |
Bouayad A. Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy. World J Clin Oncol 2025; 16(12): 115789 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i12/115789.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i12.115789 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
